Company Performance Metrics
Avigidor Scherz: Co-inventor & Scientific Advisor- Barak Palatchi: Chief Executive OfficerPast Role: Advanced Accelerator Applications, Chief Operations Officer
STEBA Biotech is a biotechnology company founded in 1996 with its headquarters in Luxembourg, its medical and regulatory team in France, and its own manufacturing facility and research center in Rehovot, Israel.
STEBA Biotech is focused on targeting cancer focally in a minimally invasive approach. STEBA Biotech vision and efforts are the
discovery, development, and future commercialization of a novel molecule and its novel mechanism of action (Focal Vascular Occluding Agent FVOA) licensed from the Weizmann Institute.
STEBA Biotech, in collaboration with the Weizmann Institute of Science (Israel), has developed a new Focal Vascular Occluding Agent (WST11) for certain types of localized cancers, upon focal light activation (specific laser devices were developed for the treatment). STEBA Biotech most advanced development of WST11 is TOOKAD® Soluble for early stage prostate cancer patients with Phase III clinical trials over Europe and in USA planned for 2012. A completely new treatment approach that may change the paradigm in prostate cancer treatment options considering quality of life for patients as a major outcome.
STEBA Biotech is committed to expand its clinical development program to other indications in oncology in targeting solid tumors in various organs.
